These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30583995)

  • 1. Lifestyle factors including diet and biochemical biomarkers in acute intermittent porphyria: Results from a case-control study in northern Norway.
    Storjord E; Dahl JA; Landsem A; Ludviksen JK; Karlsen MB; Karlsen BO; Brekke OL
    Mol Genet Metab; 2019 Nov; 128(3):254-270. PubMed ID: 30583995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dental and Periodontal Health in Acute Intermittent Porphyria.
    Storjord E; Airila-Månsson S; Karlsen K; Madsen M; Dahl JA; Landsem A; Fure H; Ludviksen JK; Fjøse JØ; Dickey AK; Karlsen BO; Waage Nielsen E; Mollnes TE; Brekke OL
    Life (Basel); 2022 Aug; 12(8):. PubMed ID: 36013449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic inflammation in acute intermittent porphyria: a case-control study.
    Storjord E; Dahl JA; Landsem A; Fure H; Ludviksen JK; Goldbeck-Wood S; Karlsen BO; Berg KS; Mollnes TE; W Nielsen E; Brekke OL
    Clin Exp Immunol; 2017 Mar; 187(3):466-479. PubMed ID: 27859020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion.
    Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DE; Harper P
    Clin Chem; 2006 Apr; 52(4):701-7. PubMed ID: 16497943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute intermittent porphyria in childhood: a population-based study.
    Hultdin J; Schmauch A; Wikberg A; Dahlquist G; Andersson C
    Acta Paediatr; 2003 May; 92(5):562-8. PubMed ID: 12839285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
    Sardh E; Rejkjaer L; Andersson DE; Harper P
    Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Porphyrin precursors and risk of primary liver cancer in acute intermittent porphyria: A case-control study of 188 patients.
    Lissing M; Wester A; Vassiliou D; Floderus Y; Harper P; Sardh E; Wahlin S
    J Inherit Metab Dis; 2023 Nov; 46(6):1186-1194. PubMed ID: 37650859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
    Sardh E; Harper P; Andersson DE; Floderus Y
    Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria.
    Aarsand AK; Petersen PH; Sandberg S
    Clin Chem; 2006 Apr; 52(4):650-6. PubMed ID: 16595824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.
    Yasuda M; Erwin AL; Liu LU; Balwani M; Chen B; Kadirvel S; Gan L; Fiel MI; Gordon RE; Yu C; Clavero S; Arvelakis A; Naik H; Martin LD; Phillips JD; Anderson KE; Sadagoparamanujam VM; Florman SS; Desnick RJ
    Mol Med; 2015 Jun; 21(1):487-95. PubMed ID: 26062020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing nutritional status of acute intermittent porphyria patients.
    García-Diz L; Murcia MA; Gris JL; Pons A; Monteagudo C; Martínez-Tomé M; Jiménez-Monreal AM
    Eur J Clin Invest; 2012 Sep; 42(9):943-52. PubMed ID: 22519672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penetrance and predictive value of genetic screening in acute porphyria.
    Baumann K; Kauppinen R
    Mol Genet Metab; 2020 May; 130(1):87-99. PubMed ID: 32067921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
    Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L;
    N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of glycerol and dextrose on porphyrin precursor excretion in acute intermittent porphyria.
    Bonkowsky HL; Magnussen CR; Collins AR; Doherty JM; Hess RA; Tschudy DP
    Metabolism; 1976 Apr; 25(4):405-14. PubMed ID: 1263834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical and financial burden of acute intermittent porphyria.
    Neeleman RA; Wagenmakers MAEM; Koole-Lesuis RH; Mijnhout GS; Wilson JHP; Friesema ECH; Langendonk JG
    J Inherit Metab Dis; 2018 Sep; 41(5):809-817. PubMed ID: 29675607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria.
    Marsden JT; Rees DC
    J Clin Pathol; 2014 Jan; 67(1):60-5. PubMed ID: 23908454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs.
    Ruspini SF; Zuccoli JR; Lavandera JV; Martínez MDC; Oliveri LM; Gerez EN; Batlle AMDC; Buzaleh AM
    Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1296-1305. PubMed ID: 29476795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Biomarkers for the Earlier Diagnosis of Kidney and Liver Damage in Acute Intermittent Porphyria.
    Storjord E; Wahlin S; Karlsen BO; Hardersen RI; Dickey AK; Ludviksen JK; Brekke OL
    Life (Basel); 2023 Dec; 14(1):. PubMed ID: 38276268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circadian rhythms in acute intermittent porphyria--a pilot study.
    Larion S; Caballes FR; Hwang SI; Lee JG; Rossman WE; Parsons J; Steuerwald N; Li T; Maddukuri V; Groseclose G; Finkielstein CV; Bonkovsky HL
    Eur J Clin Invest; 2013 Jul; 43(7):727-39. PubMed ID: 23650938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.
    Unzu C; Sampedro A; Mauleón I; Vanrell L; Dubrot J; de Salamanca RE; González-Aseguinolaza G; Melero I; Prieto J; Fontanellas A
    J Hepatol; 2010 Mar; 52(3):417-24. PubMed ID: 19815305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.